Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Lin

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Journal of Medicinal Chemistry|January 15, 2008
Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacyDeborah H Slee, Xiaohu Zhang, Manisha Moorjani, et al.
JNCI Cancer Spectrum|June 3, 2022
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate CancerNeil J Shah, Vaibhav G Patel, Xiaobo Zhong, et al.
Anesthesiology|November 10, 2025
Paravertebral or serratus anterior plane block combined with PECS I (interpectoral) blocks versus paravertebral block for mastectomy: A cluster-randomized trial of 1507 patientsHanae K Tokita, Melissa J Assel, Joanna Serafin, et al.
Journal of Medicinal Chemistry|October 25, 2008
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's diseaseXiaohu Zhang, John E Tellew, Zhiyong Luo, et al.
Journal of Medicinal Chemistry|March 1, 2008
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituentsDeborah H Slee, Yongsheng Chen, Xiaohu Zhang, et al.
Journal of Medicinal Chemistry|January 15, 2009
N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacyMarion C Lanier, Manisha Moorjani, Zhiyong Luo, et al.
Journal of Medicinal Chemistry|March 1, 2008
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationshipsDeborah H Slee, Manisha Moorjani, Xiaohu Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 TrialTanios S Bekaii-Saab, Davide Melisi, Hanneke Wilmink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2026
Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-mutant: An International Multi-Institutional StudyCameron Crowell, Nikhil P Mankuzhy, Julie Bennett, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Journal of Medicinal Chemistry|January 15, 2008
Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacyDeborah H Slee, Xiaohu Zhang, Manisha Moorjani, et al.
JNCI Cancer Spectrum|June 3, 2022
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate CancerNeil J Shah, Vaibhav G Patel, Xiaobo Zhong, et al.
Anesthesiology|November 10, 2025
Paravertebral or serratus anterior plane block combined with PECS I (interpectoral) blocks versus paravertebral block for mastectomy: A cluster-randomized trial of 1507 patientsHanae K Tokita, Melissa J Assel, Joanna Serafin, et al.
Journal of Medicinal Chemistry|October 25, 2008
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's diseaseXiaohu Zhang, John E Tellew, Zhiyong Luo, et al.
Journal of Medicinal Chemistry|March 1, 2008
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituentsDeborah H Slee, Yongsheng Chen, Xiaohu Zhang, et al.
Journal of Medicinal Chemistry|January 15, 2009
N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacyMarion C Lanier, Manisha Moorjani, Zhiyong Luo, et al.
Journal of Medicinal Chemistry|March 1, 2008
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationshipsDeborah H Slee, Manisha Moorjani, Xiaohu Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 TrialTanios S Bekaii-Saab, Davide Melisi, Hanneke Wilmink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2026
Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-mutant: An International Multi-Institutional StudyCameron Crowell, Nikhil P Mankuzhy, Julie Bennett, et al.
Pageof 10